Press Releases.

-Expanded Development of RG-101 through Clinical Trial Collaboration with GSK to Achieve Potential Single Visit HCV Therapy -

- Long-Acting Parenteral Formulation of GSK2878175 Being Developed; Co-Administration with RG-101 May Enable Single Visit Therapy for HCV Patients

RG-012 Shown to Directly Inhibit microRNA-21, Demonstrates Favorable Preclinical Profile Supporting Proof of Mechanism and Clinical Development

-Phase I Clinical Data will be Featured in Viral Hepatitis Plenary Session-

-Advanced 'Clinical Map Initiative' with Start of Key Clinical Trials for RG-101 and RG-012-